Company profile
Oncotelic Therapeutics, Inc.
OTC: OTLC · Healthcare · Biotechnology
#1064 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
46DFH 70DQ 23GM 13SS 65
v0.1 · 65/100 weight · provisional
↑ net margin, return on equity · ↓ growth stability, revenue growth (YoY)
Methodology →Revenue TTM
$250.0k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
$249.3M
Employees
41
as of 2026-08-21
Market cap
$17.7M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$70.0k$70.0k2023
Net income$249.3M$249.3M2025
Operating income-$3.2M-$3.2M2025
Total assets$393.1M$393.1M2025
Liabilities$131.4M$131.4M2025
Equity$262.8M$262.8M2025
Revenue trend
FY2012 – FY2023 · USD
FY12
FY13
FY20
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Oncotelic Therapeutics, Inc.’s revenue?
Oncotelic Therapeutics, Inc. booked $70.0k in FY2023 revenue, contracting 96% year over year — among the slowest-growing Healthcare companies we track, at a 356114.0% net margin.
Peers · Healthcare
PAVmed Inc.40DExlites Holdings International, Inc.54DeXoZymes, Inc.24DMYND Life Sciences Inc.——Vivos Inc.48DNeutra Corp.——Neighbors
Los Angeles →Key facts
CEOVuong Trieu
SectorHealthcare
IndustryBiotechnology
HeadquartersAgoura Hills, CA
ExchangeOTC: OTLC
Employees41
IPO date1993-08-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.